A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors
This is an open label Phase Ia/Ib trial to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of IBI360 monotherapy in Advanced or Metastatic Solid Tumors
Advanced Solid Tumor
DRUG: IBI 360 Injection|DRUG: IBI 360 Injection Sintilimab
Safety and tolerance, Participant safety is characterized by frequency and severity of adverse events(according to NCI CTCAE 5.0), up to 90 days following last dose|Recommended Phase 2 Dose (RP2D), A recommended phase 2 dose will be determined based on safety data including dose limiting toxicities, preliminary efficacy data, and PK data, up to 21 days following last dose level
Efficacy, Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1)., Subjects were randomized 6 months and 1 year later|Pharmacokinetics, Area under plasma concentration vs time curve(AUC), Up to 48 weeks following first dose|Immunogenicity, Incidence of anti-drug antibodies (ADA) will be measured, up to 90 days following last dose|Pharmacokinetics, Peak plasma concentration(Cmax), Up to 48 weeks following first dose|Pharmacokinetics, Up to 48 weeks following first dose, Clearance（CL）|Pharmacokinetics, Apparent volumeof distribution（V）, Up to 48 weeks following first dose|Pharmacokinetics, Terminal Half Life（T1/2）, Up to 48 weeks following first dose
Phase Ia is dose escalation and dose expansion study of IBI360 monotherapy and IBI360 in combination with sintilimab in advanced or metastatic Solid Tumors; Phase Ib is an multi-cohort trial of pancreatic carcinoma, HER2 negative gastric adenocarcinoma, advanced or metastatic solid tumors to evaluate safety and preliminary efSficacy of IBI360 in combination with sintilimab and (or) chemotherapy or IBI360 monotherapy.